非甾体盐皮质激素受体拮抗剂与慢性肾脏病的心肾结局
综述总结非甾体盐皮质激素受体拮抗剂(MRA)在慢性肾脏病(CKD)合并糖尿病患者中改善心肾结局的现有证据,并讨论其与心衰及CKD基础治疗联用的价值,指出该类药物已获指南支持且可能减少高钾血症等不良反应。
要点
- 非甾体MRA是糖尿病肾脏病患者新兴治疗选择,已获指南支持。
- 非甾体MRA保留类特异性心肾获益,可能有助于减轻CKD患者高钾血症等不良反应。
- 综述总结非甾体MRA改善CKD合并糖尿病患者心肾结局及与基础治疗联用的证据。
核心结论
- 非甾体MRA保留类特异性心肾获益,可能有助于减轻CKD患者的不良反应尤其是高钾血症。
研究设计与样本
- 综述总结非甾体MRA用于改善CKD合并糖尿病患者心肾结局及与其他心衰和CKD基础治疗联用的现有证据。
主要发现
- 甾体MRA已显示改善心衰患者临床结局,但使用率显著不足,晚期CKD患者尤为明显。
- 非甾体MRA是糖尿病肾脏病患者新兴治疗选择,已获指南支持。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The burden of adverse cardiorenal outcomes among patients with the trifecta of diabetes, heart failure (HF) and chronic kidney disease (CKD) remains high. Steroidal mineralocorticoid receptor antagonists (MRAs) have been shown to improve clinical outcomes in patients with HF, however, there is significant underutilization of these agents, especially in patients with advanced CKD. Non-steroidal MRAs are an emerging therapeutic option for patients with diabetic kidney disease and are now guideline-supported in this population. Non-steroidal MRAs have a unique pharmacological profile distinct from their steroidal counterparts that retains the class-specific cardiorenal benefits but may help mitigate adverse effects, especially hyperkalaemia, in patients with CKD. In this review we summarize the current evidence on the use of non-steroidal MRAs for improving cardiorenal outcomes in patients with CKD and diabetes, as well as for combination use alongside other foundational medical therapies used in HF and CKD.
引用
- Lo KB, Rangaswami J, Vaduganathan M, et al. Non-steroidal mineralocorticoid receptor antagonists and cardiorenal outcomes in chronic kidney disease. Nephrol Dial Transplant. 2023. PMID: 36472546. doi:10.1093/ndt/gfac322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。